11 results about "Blocking drug" patented technology

The utility model discloses a novel nerve block needle which comprises an injector, the bottom of the injector is connected with a connecting cylinder in a clamped mode, the bottom of the connecting cylinder is fixedly connected with a puncture needle head, the top of the injector is fixedly connected with a connecting column, a sliding groove is formed in the connecting column, and a rotary knob is arranged at the top of the injector. The length and the diameter of the puncture needle are designed according to different clinical requirements so as to adapt to nerve block operation of different parts, the catheter needle is located in the puncture needle, the front end of the catheter needle is provided with a telescopic umbrella-shaped structure, and after the puncture needle punctures a subcutaneous target area, the front end of the catheter needle stretches out, and the umbrella-shaped structure is opened. The umbrella-shaped structure is made of a flexible medical material, it is ensured that surrounding tissue cannot be injured when the catheter needle is opened, the front end of the catheter needle is round and blunt so that the risk of injury to the tissue can be further reduced, and when the catheter needle reaches a position needing blocking, blocking medicine can be evenly injected in a designated area through unfolding of the umbrella-shaped structure.

The invention discloses a customized intelligent drug release monitoring trigeminal nerve block microneedle system, and relates to the technical field of medical equipment. Comprising a radiography mechanism, and the radiography mechanism comprises a workbench, a C-shaped arm, an X-ray bulb tube and an image detector; the head limiting assembly is used for fixing the head of a patient, the positioning assembly is arranged on the head limiting assembly, the positioning assembly comprises an arc-shaped support and a positioning plate used for positioning an oval hole, the positioning plate can be adjusted around the arc-shaped support, a plurality of needle holes are formed in the positioning plate, and the central axis of any needle hole can coincide with the central axis of the oval hole; when the foramen ovale is positioned, a metal probe is inserted into the needle hole, and after positioning is completed, a microneedle for conveying blocking medicine is inserted through the needle hole. According to the microneedle system for customized intelligent drug release monitoring of trigeminal nerve block, after the head of a patient is fixed, the radiography mechanism is matched with the positioning assembly to obtain the position of the foramen foramen ovale, and the accuracy and safety of blocking drug delivery are improved.

The invention relates to a benzopiperidine biquaternary ammonium salt compound and application thereof in medicine, in particular to a compound shown in a general formula (I) or a stereoisomer, a racemate, a tautomer, pharmaceutically acceptable salt, an intermediate and a pharmaceutical composition of the compound, and application of the compound in preparation of neuromuscular blocking drugs.

The present application relates to the technical field of medical devices, in particular to a chemotherapy outpatient anti-extravasation chemotherapy dosing device, comprising a transfusion tube, a hydraulic collection assembly is arranged on the transfusion tube, a drip speed collection assembly is arranged outside the drip tube, the hydraulic collection assembly is signal connected with a controller, the controller is electrically connected with a strain collection assembly, whether the current transfusion process is abnormal is comprehensively judged through the hydraulic change information of the drug solution delivery and the drip speed change information in the drip tube, and whether there is drug solution extravasation is judged in combination with the tension change of the patient's puncture point; a valve assembly is arranged on the transfusion tube, and a drug solution recovery assembly is further arranged below the valve assembly, when drug solution extravasation occurs in the patient's transfusion process, the valve assembly is driven to block the drug solution delivery, and the drug solution recovery assembly recovers the residual drug solution in the transfusion tube. The present application integrates hydraulic, drip speed and skin tension multi-dimensional data monitoring, when chemotherapy drug delivery extravasation is detected, the drug solution delivery is blocked, and the residual drug solution is cleaned and recovered, so that the defect of continuous drug delivery after existing drug delivery extravasation is solved.

The invention belongs to the technical field of biological medicine, discloses application of PARVA as a target spot in treatment of pulmonary fibrosis, and particularly relates to application of a PARVA down-regulating agent in preparation of medicine for treating pulmonary fibrosis. Aiming at the problem that the existing pulmonary fibrosis treatment medicine is difficult to target the pain point of a core pathological link, the medicine disclosed by the invention takes a PARVA gene in lung fibroblasts or an encoding protein thereof as a target spot, and comprises a knockdown medicine (such as shRNA, siRNA and miRNA), a knockout medicine (such as a Cre / LoxP system) or a targeted blocking medicine (such as a small molecule compound and polypeptide), preferably an injection, an atomizing agent and other dosage forms. The down-regulating agent realizes inhibition of activation and proliferation of lung fibroblasts and extracellular matrix deposition by down-regulating PARVA expression or inhibiting PARVA activity, so as to block pulmonary fibrosis progress. The invention has the advantages of strong target specificity, clear action mechanism, various drug types, obvious treatment effect and the like, and provides a new effective strategy for pulmonary fibrosis treatment.

The utility model belongs to the technical field of medicines, and particularly relates to a medicine code scanning and racking device for a pharmacy. Comprising a working machine table, a conveying device is arranged at the side end of the working machine table, a limiting structure is arranged at the top end of the conveying device, and a driving structure, a suction structure, a weighing device and a code scanning structure are arranged at the top end of the working machine table. Through the limiting structure, the driving structure and the suction structure, the limiting structure can be used for blocking drugs on the conveying equipment, the drugs on the inner side of the limiting structure can be transferred to the working machine table through the suction structure in cooperation with the driving structure, and a weighing device and a code scanning structure are promoted to conduct code scanning input on information of the drugs; according to the technical scheme, automatic operation is achieved in the medicine information input process, the manual input mode is avoided, the medicine code scanning and racking efficiency is improved, the problems that medicine is damaged or code scanning information is wrong due to improper operation are solved, and powerful technical support is provided for medicine management of a pharmacy.

The invention provides a sacral canal block drug effect monitoring device and method.The sacral canal block drug effect monitoring device comprises a finger clamping device and a display device, a sensor unit used for obtaining the perfusion index of a patient and a chip unit used for receiving and processing signals of the sensor unit are arranged in the finger clamping device, and the display device is used for displaying the perfusion index value; wherein the finger clamping device is provided with a clamping groove for containing the fingers of a patient, the sensor unit is arranged at the inner end of the clamping groove, an elastic film is arranged on the inner wall of the clamping groove, an air cavity is formed between the elastic film and the inner wall of the clamping groove, and a cushioning block is elastically arranged on the outer side face of the finger clamping device. An adjusting mechanism connected with the cushioning block is arranged on the finger clamping device, and the adjusting mechanism is used for inflating the air cavity to promote the elastic film to expand and cling to the finger of the patient; the expansion degree of the elastic film is conveniently adjusted, so that the device can adapt to the thicknesses of fingers of different patients, and the application range of the device is widened.

The present invention belongs to the field of biotechnology, and particularly relates to an application of Caerin 1.1 / 1.9 combined with an anti-CD47 antibody in preparing a drug for treating melanoma. In the present invention, an amino acid sequence of the Caerin 1.1 is shown in SEQ ID NO.1; and an amino acid sequence of the Caerin 1.9 is shown in SEQ ID NO.2. The Caerin 1.1 / 1.9 of the present invention may promote B16 cells to highly express CD47 while leading to apoptosis of the B16 cells, promote macrophages to phagocytose tumor cells in the presence of anti-CD47 antibodies, improve the curative effect of the Caerin 1.1 / 1.9, which is also superior to that of a single anti-CD47 antibody, and lays a foundation for expanding the application of CD47 inhibition / blocking drugs.

The invention relates to a biquaternary ammonium salt compound and application thereof in medicine, in particular to a compound shown in a general formula (I) or a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or co-crystal of the compound, an intermediate and a pharmaceutical composition of the compound, and application of the compound in preparation of neuromuscular blocking drugs. # imgabs0 #

A method for the fail-safe termination of in vivo drug delivery from an implantable drug delivery system, the method comprising: providing an implantable drug delivery system comprising: a housing having a reservoir for containing a drug, and a port for dispensing the drug to a patient; and an emergency deactivation unit disposed between the reservoir and the port, the emergency deactivation unit comprising a composite structure comprising a biocompatible ferromagnetic mesh open to fluid flow and a hydrophobic meltable material, the hydrophobic meltable material comprising at least one hole therein for enabling a fluid to pass through the hydrophobic meltable material; implanting the implantable drug delivery system within a patient; enabling the drug to flow from the reservoir, through the at least one hole in the hydrophobic meltable material and out the port; and when drug flow is to be terminated, applying a magnetic field to the composite structure, such that a current is induced in the ferromagnetic mesh which heats the ferromagnetic mesh and melts the hydrophobic meltable material, thereby closing the at least one hole in the hydrophobic meltable material and blocking drug delivery to the patient.

A method for the fail-safe termination of in vivo drug delivery from an implantable drug delivery system, the method comprising: providing an implantable drug delivery system comprising: a housing having a reservoir for containing a drug, and a port for dispensing the drug to a patient; and an emergency deactivation unit disposed between the reservoir and the port, the emergency deactivation unit comprising a composite structure comprising a biocompatible ferromagnetic mesh open to fluid flow and a hydrophobic meltable material, the hydrophobic meltable material comprising at least one hole therein for enabling a fluid to pass through the hydrophobic meltable material; implanting the implantable drug delivery system within a patient; enabling the drug to flow from the reservoir, through the at least one hole in the hydrophobic meltable material and out the port; and when drug flow is to be terminated, applying a magnetic field to the composite structure, such that a current is induced in the ferromagnetic mesh which heats the ferromagnetic mesh and melts the hydrophobic meltable material, thereby closing the at least one hole in the hydrophobic meltable material and blocking drug delivery to the patient.